Utilizing polydispersity in composite fibrous based sound absorbing materials

The distribution of fiber diameters plays a crucial role in the transport and sound absorbing properties of a three-dimensional random fibrous (3D-RF) composites. Conventionally, volume-weighted averaging of fiber diameters has been utilized as an appropriate microstructural descriptor to predict the static viscous permeability of 3D-RF composites. However, the long wavelength acoustical properties of a 3D-RF composites are also sensitive to the smallest fibers, this is particularly true in the high-frequency regime. In our recent research, we demonstrated that an inverse volume-weighted averaging of fiber diameters can effectively serve as a complementary microstructural descriptor to capture the high-frequency behavior of polydisperse fibrous media. In the present work, we review the identification of two representative volume elements (RVEs) which relies on the reconstruction of 3D-RF composites having volume-weighted and inverse-volume weighted averaged fiber diameters, respectively in the low-frequency and high frequency regimes. We examine the implication of such a weighting procedure on the transport and sound absorbing properties of polydisperse fibrous media, highlighting their potential advantages. Furthermore, we discuss the challenges associated with this research field. Finally, we provide a brief perspective of the future directions and opportunities for advancing this area of study, aiming to overcome challenges and extend the benefits of employing polydispersity as a new lever for the optimization of 3D-RF composites in sound-absorbing materials.Comment: 10 pages, 7 figure

Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry

The European Increlex® Growth Forum Database (Eu-IGFD) is an ongoing surveillance registry (NCT00903110) established to collect long-term safety and effectiveness data on the use of recombinant human insulin-like growth factor-1 (rhIGF-1, mecasermin, Increlex) for the treatment of children/adolescents with severe primary insulin-like growth factor-1 deficiency (SPIGFD). Objective: This analysis of Eu-IGFD data aimed to identify the frequency and predictive factors for hypoglycemia adverse events (AEs) in children treated with rhIGF-1. Methods: Data were collected from December 2008 to May 2021. Logistic regression was performed to identify predictive risk factors for treatment-induced hypoglycemia AEs. Odds ratios (ORs) are presented with 95% CIs for each factor. Results: In total, 306 patients were enrolled in the registry; 84.6% were diagnosed with SPIGFD. Patients who experienced ≥ 1 hypoglycemia AE (n = 80) compared with those with no hypoglycemia AEs (n = 224) had a lower mean age at treatment start (8.7 years vs 9.8 years), a more frequent diagnosis of Laron syndrome (27.5% vs 10.3%), and a history of hypoglycemia (18.8% vs 4.5%). Prior history of hypoglycemia (OR 0.25; 95% CI: [0.11; 0.61]; P = .002) and Laron syndrome diagnosis (OR 0.36; 95% CI: [0.18; 0.72]; P = .004) predicted future hypoglycemia AEs. Total hypoglycemia AEs per patient per treatment year was 0.11 and total serious hypoglycemia AEs per patient per treatment year was 0.01. Conclusion: Hypoglycemia occurs more frequently in patients with prior history of hypoglycemia and/or Laron syndrome compared with patients without these risk factors, and these patients should be carefully monitored for this AE throughout treatment

Effect of LHRH analogs on lower urinary tract symptoms associated with advanced prostate cancer in real clinical practice : ANALUTS study

To estimate the prevalence of lower urinary tract symptoms (LUTS) in patients with prostate cancer scheduled to receive LHRH analogs, and to assess the effectiveness of LHRH analogs on LUTS in patients presenting moderate/severe symptoms. Prospective, noninterventional, multicenter study conducted at 28 centers in Spain and Portugal. LUTS were evaluated using the International Prostate Symptom Score (IPSS) at baseline, 24 and 48 weeks after initiation of treatment. Subanalyses were performed according to age and concomitant treatment (radiotherapy, alpha-blockers, and antiandrogens). A total of 354 patients were treated with LHRH analogs for 48 weeks. The percentage of patients with moderate/severe LUTS (IPSS > 7) decreased from 60.2% (n = 213/354) at baseline to 52.8% (n = 187/354) at Week 48. Among patients with moderate/severe LUTS at baseline: 73.7% (n = 157/213) still had moderate/severe LUTS at Week 48; percentage reductions of patients with LUTS at Week 48 were statistically significant (p < 0.05) overall and by age or concomitant treatment, except for alpha-blockers (84.2% patients receiving them still had moderate/severe LUTS at Week 48). All IPSS items, including quality of life for urinary symptoms, improved throughout the study. The only predictor of response to treatment with LHRH analogs that improved IPSS by 3 points after 48 weeks was baseline testosterone levels. Lower baseline testosterone levels were associated with greater improvement in IPSS after treatment with LHRH analogs (odds ratio 0.998, 95% confidence interval 0.996-1.000, p = 0.0277). LHRH analogs have a positive effect in patients with locally advanced or metastatic prostate cancer presenting moderate/severe LUTS regardless of age or concomitant treatment received (radiotherapy, antiandrogens, or alpha-blockers)

Early clinical experience with cabozantinib for advanced renal cell carcinoma in the UK: real-world treatment pathways and clinical outcomes

BACKGROUND: Cabozantinib monotherapy is approved in the UK for patients with treatment-naïve intermediate- or poor-risk advanced renal cell carcinoma (aRCC), or patients who received prior vascular endothelial growth factor-targeted therapy. Data are limited on the real-world use of cabozantinib for aRCC. PATIENTS AND METHODS: CERES (NCT03696407) was a retrospective study of patients with aRCC who received cabozantinib through the UK managed access programme (MAP; August 2016-July 2017), at which time cabozantinib had European regulatory approval for second- or later-line use only. The study objectives were to characterize aRCC treatment patterns and evaluate cabozantinib effectiveness. Outcomes were stratified by cabozantinib treatment line, MAP treatment date (months 0-7 vs. 8-12) and (post hoc) Charlson Comorbidity Index (CCI; ≥ 6 vs. &lt; 6). RESULTS: Of 100 patients included, 99% had stage IV disease, 63% had a CCI ≥ 6 and 81% had an Eastern Cooperative Oncology Group Performance Status 0-1. Median (range) duration of follow-up was 10.8 (0.4-33.5) months. Cabozantinib was administered as second-line, third-line and fourth- or later-line in 41%, 31% and 28% of patients, respectively. Most patients (84%) initiated cabozantinib at 60 mg. Average (range) cabozantinib dose was 45.5 (19.6-59.8) mg/day; 66% of patients had ≥ 1 dose reduction. Disease progression was the most common reason for discontinuation (65.1%). Median (95% confidence interval) progression-free survival (PFS) and overall survival (OS) were 6.01 (5.16-7.85) and 10.84 (7.92-16.85) months, respectively. Overall response rate was 34.5%; disease control rate 70.1% and duration of response 6.9 (1.8-26.9) months. No significant differences in survival estimates were observed between treatment line or treatment date subgroups. Total CCI score ≤ 6 (vs. &gt; 6) was associated with prolonged median PFS and OS. CONCLUSION: Cabozantinib demonstrated clinical activity in this UK real-world aRCC population. The results provide a benchmark for future real-world studies in aRCC

Diagnostic and therapeutic care pathway for fibromyalgia

Early diagnosis and timely and appropriate treatments positively influence the history of fibromyalgia syndrome (FM), with favourable repercussions at clinical, psychological, social and economic levels. Notwithstanding, there are still significant problems with timeliness of diagnosis, access to pharmacological therapies - particularly to innovative ones - and appropriate and effective taking in charge of patients. All the aforementioned factors have a great impact on FM patients' quality of life. Indeed, even though the World Health Organisation recognised FM as a chronic condition in the International Classification of Diseases 10th edition (ICD-10), many countries still fail to recognise the syndrome, and this negatively influences the capability to appropriately protect and care for patients. This is the case in several European Countries. In Italy, a few Regions have started to put in place precise indications for people suffering from FM, aiming at the implementation of diagnostic-therapeutic pathways. The Diagnostic-Therapeutic Care Pathway (DTCP) provides an important tool to meet the needs of patients suffering from chronic diseases. They present the organisation of an integrated assistance network. This includes a seamless path for disease prevention, diagnosis and treatment, by means of cooperation among physicians and other healthcare professionals

Fibromyalgia position paper

Fibromyalgia syndrome is one of the most common causes of chronic widespread pain, but pain accompanies a wide range of ancillary symptoms. To date, its aetiopathogenesis remains elusive, and diagnosis is exquisitely clinical, due to the lack of biomarkers or specific laboratory alterations in fibromyalgia patients. This position paper has the purpose to summarise the current scientific knowledge and expert opinions about the main controversies regarding fibromyalgia syndrome, namely: (i) fibromyalgia definition and why it is still not recognised in many countries as a distinct clinical entity; (ii) fibromyalgia severity and how to evaluate treatment outcome; (iii) how to treat fibromyalgia and which is a correct approach to fibromyalgia patients

The IASLC Lung Cancer Staging Project: A Renewed Call to Participation

Over the past two decades, the International Association for the Study of Lung Cancer (IASLC) Staging Project has been a steady source of evidence-based recommendations for the TNM classification for lung cancer published by the Union for International Cancer Control and the American Joint Committee on Cancer. The Staging and Prognostic Factors Committee of the IASLC is now issuing a call for participation in the next phase of the project, which is designed to inform the ninth edition of the TNM classification for lung cancer. Following the case recruitment model for the eighth edition database, volunteer site participants are asked to submit data on patients whose lung cancer was diagnosed between January 1, 2011, and December 31, 2019, to the project by means of a secure, electronic data capture system provided by Cancer Research And Biostatistics in Seattle, Washington. Alternatively, participants may transfer existing data sets. The continued success of the IASLC Staging Project in achieving its objectives will depend on the extent of international participation, the degree to which cases are entered directly into the electronic data capture system, and how closely externally submitted cases conform to the data elements for the project

ETUDE DES MECANISMES DE SENSIBILISATION CENTRALE ET PERIPHERIQUE MODULANT L'ACTION ANTINOCICEPTIVE DE LA MORPHINE AU MOYEN DE TESTS COMPORTEMENTAUX DANS LES MODELES ANIMAUX DE DOULEURS INFLAMMATOIRE ET NEUROPATHIQUE

NOUS AVONS EVALUE L'EFFET DE DIFFERENTES SUBSTANCES SUR LE COMPORTEMENT ANTINOCICEPTIFOBSERVE DANS DES MODELES ANIMAUX DE DOULEUR INFLAMMATOIRE ET NEUROPATHIQUE. 1- LA COMPARAISON DES MODELES DE POLYARTHRITE INDUITE PAR L'INJECTION D'ADJUVANT DE FREUND ET DE MONONEUROPATHIE INDUITE PAR LA LIGATURE DU NERF SCIATIQUE MONTRE QUE LA CALCITONINE EST SANS EFFET DANS LES DEUX MODELES, ALORS QUE LA GUANETHIDINE, INDUIT UN EFFET TRANSITOIRE SUR LE TEST MECANIQUE, ET UN EFFET PERSISTANT SUR LE TEST THERMIQUE AU FROID DANS LA MONONEUROPATHIE. 2- DANS LE MODELE DE L'ARTHRITE LOCALISEE INDUITE PAR L'INJECTION INTRA-PLANTAIRE DE CARRAGENINE, LES EFFETS PERIPHERIQUES DE LA MORPHINE SONT PLUS IMPORTANTS APRES UNE INFLAMMATION AIGUE QUE LORS D'INFLAMMATIONS REPETEES, ALORS QUE L'ON OBSERVE L'INVERSE POUR LES EFFETS DE LA MORPHINE INTRA-VEINEUSE. LES EFFETS DE LA MORPHINE INTRA-PLANTAIRE SUR L'INTENSITE DE L'INFLAMMATION LIEE A LA CARRAGENINE SONT VARIABLES ET LIES A LA DOSE UTILISEE, LES DOSES MOYENNES POUVANT INDUIRE DES EFFETS PRO-INFLAMMATOIRES. 3- LES EFFETS ANTINOCICEPTIFS D'UN INHIBITEUR MIXTE DE LA DEGRADATION DES ENKEPHALINASES, LE PC12, SONT REDUITS LORS DE L'INDUCTION D'UNE POLYARTHRITE A ADJUVANT DE FREUND ET PLAFONNENT RAPIDEMENT, SUGGERANT LES LIMITES DE L'ACTION ANTINOCICEPTIVE DES PEPTIDES OPIOIDES ENDOGENES DANS LE CAS DE L'INFLAMMATION. 4- LA MODULATION DES EFFETS ANTINOCICEPTIFS DE LA MORPHINE PAR UN ANTAGONISTE DES RECEPTEURS B DE LA CHOLECYSTOKININE (CCK), LE L-365,260 A ETE OBSERVEE PENDANT UNE PERIODE RESTREINTE, ESSENTIELLEMENT AU MAXIMUM DE L'INFLAMMATION (3 HEURES APRES LA CARRAGENINE) ET POUR UNE DOSE FAIBLE (0,1 MG/KG DE MORPHINE I.V.). DANS LE MODELE DE DOULEUR MONONEUROPATHIQUE, LE L-365,260 AUGMENTE EGALEMENT LES EFFETS ANTINOCICEPTIFS DE LA MORPHINE MAIS AUSSI DE FACON RESTREINTE, POUR CERTAINS STIMULUS ET UNE FAIBLE DOSE DE MORPHINE (0,1 MG/KG DE MORPHINE I.V.). 5- L'ETUDE DE L'ACTION D'UN ANTAGONISTE DES RECEPTEURS NMDA, LE (+)-HA966 SUGGERE QUE L'ACTIVATION DES RECEPTEURS NMDA EST IMPLIQUEE DANS LES MECANISMES DE LA DOULEUR INFLAMMATOIRE, A LA PERIPHERIE COMME AU NIVEAU CENTRAL, DE FACON PLUS MARQUEE DANS UNE INFLAMMATION AIGUE QUE DANS UNE INFLAMMATION RECURRENTE. LE (+)-HA966 AMPLIFIE L'ACTION ANTINOCICEPTIVE DE LA MORPHINE, ADMINISTREE PAR VOIE INTRA-VEINEUSE OU PERIPHERIQUE, D'AUTANT PLUS QUE LE (+)-HA966 EST INJECTE PREVENTIVEMENT, AVANT TOUTE INFLAMMATION ET PAR VOIE I.PL.PARIS-BIUSJ-Thèses (751052125) / SudocCentre Technique Livre Ens. Sup. (774682301) / SudocPARIS-BIUSJ-Physique recherche (751052113) / SudocSudocFranceF

TRAITEMENT PAR LA TOXINE BOTULIQUE DE LA SPASTICITE DES MEMBRES SUPERIEURS APRES UN ACCIDENT VASCULAIRE CEREBRAL ET BENEFICE FONCTIONNEL

LILLE2-BU Santé-Recherche (593502101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Effectiveness and safety of rhIGF1 therapy n patients with or without Laron syndrome

Objective: The European Increlex (R) Growth Forum Database Registry monitors the effectiveness and safety of recombinant human insulin-like growth factor-1 (rhIGF1; mecasermin, Increlex (R)) therapy in patients with severe primary IGF1 deficiency (SPIGFD). We present data from patients with and without a reported genetic diagnosis of Laron syndrome (LS). Design: Ongoing, open-label, observational registry (NCT00903110). Methods: Children and adolescents receiving rhIGF1 therapy from 10 European countries were enrolled in 2008-2017 (n = 242). The treatment-naive/prepubertal (NPP) cohort (n = 138) was divided into subgroups based on reported genetic diagnosis of LS (n = 21) or non-LS (n = 117). Multivariate analysis of the NPP-non-LS subgroup was conducted to identify factors predictive of growth response (first-year-height standard deviation score (SDS) gain &amp;gt;= 0.3). Assessments included change in height and weight over 5 years and adverse events (AEs). Results: Height SDS gain from baseline was greater in the NPP-LS than the NPP-non-LS subgroup after 1 years treatment (P &amp;lt; 0.05). In the NPP-non-LS subgroup, 56% were responders; young age at baseline was a positive independent predictive factor (P &amp;lt; 0.001). NPP-non-LS-responders and the NPP-LS subgroup had a similar mean age (6.07 years vs 7.00 years) at baseline and height SDS gain in year 1 (0.64 vs 0.70), although NPP-non-LS-responders were taller (P &amp;lt; 0.001) at baseline. BMI SDS changes did not differ across subgroups. Treatment-emergent AEs were experienced by 65.3% of patients; hypoglycaemia was most common. Conclusions: In most NPP children with SPIGFD, with or without LS, rhIGF1 therapy promotes linear growth. The safety profile was consistent with previous studies.Funding Agencies|Ipsen</p